Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2 a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C

R. Perrillo, K. D. Rothstein, R. Rubin, Imtiaz Alam, J. Imperial, G. Harb, S. Hu, W. Klaskala

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The on-treatment impact of interferon-based therapies on quality of life (QOL), work productivity, and medical resource utilization has not been systematically studied. We evaluated the effects of treatment with peginterferon alpha (pegIFNα) 2a monotherapy and the combination of interferon alpha (IFNα) 2b plus ribavirin (RBV) on health-related QOL, work productivity and resource utilization. A total of 412 patients with hepatitis C infection were randomized to open-label treatment with either pegIFNα 2a (n = 206) or IFNα 2b/RBV (n = 206). PegIFNα 2a was administered subcutaneously at a dose of 180 μg once weekly for 48 weeks; and IFNα 2b/RBV at doses of 3 MU thrice weekly subcutaneously and 1000-1200 mg/day orally. Outcome measures included the SF-36 Health Survey Questionnaire and additional generic and specific scales. During treatment, for all SF-36 summary and Hepatitis Quality of Life Questionnaire (HQLQ)-specific scales, the pegIFNα 2a group experienced less impairment than did the IFNα 2b/RBV patients. The between-treatment differences were significant for many of the scores particularly in the first 24 weeks of treatment. Across all measures of work functioning and productivity at each visit, patients randomized to pegIFNα 2a treatment showed less impairment relative to the group treated with IFNα 2b/RBV. Hence treatment with pegIFNα 2a relative to IFNα 2b/RBV minimizes the adverse impact of therapy on health-related QOL. Patients randomized to pegIFNα 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy.

Original languageEnglish (US)
Pages (from-to)157-165
Number of pages9
JournalJournal of Viral Hepatitis
Volume11
Issue number2
DOIs
StatePublished - Mar 1 2004

Fingerprint

interferon alfa-2b
Ribavirin
Chronic Hepatitis C
Quality of Life
Therapeutics

Keywords

  • Hepatitis C infection
  • Interferon alpha
  • Quality of life
  • Utilization of medical resources

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2 a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. / Perrillo, R.; Rothstein, K. D.; Rubin, R.; Alam, Imtiaz; Imperial, J.; Harb, G.; Hu, S.; Klaskala, W.

In: Journal of Viral Hepatitis, Vol. 11, No. 2, 01.03.2004, p. 157-165.

Research output: Contribution to journalArticle

@article{9e9c4d119c4c413c89501cfa9f4b8ad9,
title = "Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2 a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C",
abstract = "The on-treatment impact of interferon-based therapies on quality of life (QOL), work productivity, and medical resource utilization has not been systematically studied. We evaluated the effects of treatment with peginterferon alpha (pegIFNα) 2a monotherapy and the combination of interferon alpha (IFNα) 2b plus ribavirin (RBV) on health-related QOL, work productivity and resource utilization. A total of 412 patients with hepatitis C infection were randomized to open-label treatment with either pegIFNα 2a (n = 206) or IFNα 2b/RBV (n = 206). PegIFNα 2a was administered subcutaneously at a dose of 180 μg once weekly for 48 weeks; and IFNα 2b/RBV at doses of 3 MU thrice weekly subcutaneously and 1000-1200 mg/day orally. Outcome measures included the SF-36 Health Survey Questionnaire and additional generic and specific scales. During treatment, for all SF-36 summary and Hepatitis Quality of Life Questionnaire (HQLQ)-specific scales, the pegIFNα 2a group experienced less impairment than did the IFNα 2b/RBV patients. The between-treatment differences were significant for many of the scores particularly in the first 24 weeks of treatment. Across all measures of work functioning and productivity at each visit, patients randomized to pegIFNα 2a treatment showed less impairment relative to the group treated with IFNα 2b/RBV. Hence treatment with pegIFNα 2a relative to IFNα 2b/RBV minimizes the adverse impact of therapy on health-related QOL. Patients randomized to pegIFNα 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy.",
keywords = "Hepatitis C infection, Interferon alpha, Quality of life, Utilization of medical resources",
author = "R. Perrillo and Rothstein, {K. D.} and R. Rubin and Imtiaz Alam and J. Imperial and G. Harb and S. Hu and W. Klaskala",
year = "2004",
month = "3",
day = "1",
doi = "10.1046/j.1365-2893.2003.00482.x",
language = "English (US)",
volume = "11",
pages = "157--165",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2 a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C

AU - Perrillo, R.

AU - Rothstein, K. D.

AU - Rubin, R.

AU - Alam, Imtiaz

AU - Imperial, J.

AU - Harb, G.

AU - Hu, S.

AU - Klaskala, W.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - The on-treatment impact of interferon-based therapies on quality of life (QOL), work productivity, and medical resource utilization has not been systematically studied. We evaluated the effects of treatment with peginterferon alpha (pegIFNα) 2a monotherapy and the combination of interferon alpha (IFNα) 2b plus ribavirin (RBV) on health-related QOL, work productivity and resource utilization. A total of 412 patients with hepatitis C infection were randomized to open-label treatment with either pegIFNα 2a (n = 206) or IFNα 2b/RBV (n = 206). PegIFNα 2a was administered subcutaneously at a dose of 180 μg once weekly for 48 weeks; and IFNα 2b/RBV at doses of 3 MU thrice weekly subcutaneously and 1000-1200 mg/day orally. Outcome measures included the SF-36 Health Survey Questionnaire and additional generic and specific scales. During treatment, for all SF-36 summary and Hepatitis Quality of Life Questionnaire (HQLQ)-specific scales, the pegIFNα 2a group experienced less impairment than did the IFNα 2b/RBV patients. The between-treatment differences were significant for many of the scores particularly in the first 24 weeks of treatment. Across all measures of work functioning and productivity at each visit, patients randomized to pegIFNα 2a treatment showed less impairment relative to the group treated with IFNα 2b/RBV. Hence treatment with pegIFNα 2a relative to IFNα 2b/RBV minimizes the adverse impact of therapy on health-related QOL. Patients randomized to pegIFNα 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy.

AB - The on-treatment impact of interferon-based therapies on quality of life (QOL), work productivity, and medical resource utilization has not been systematically studied. We evaluated the effects of treatment with peginterferon alpha (pegIFNα) 2a monotherapy and the combination of interferon alpha (IFNα) 2b plus ribavirin (RBV) on health-related QOL, work productivity and resource utilization. A total of 412 patients with hepatitis C infection were randomized to open-label treatment with either pegIFNα 2a (n = 206) or IFNα 2b/RBV (n = 206). PegIFNα 2a was administered subcutaneously at a dose of 180 μg once weekly for 48 weeks; and IFNα 2b/RBV at doses of 3 MU thrice weekly subcutaneously and 1000-1200 mg/day orally. Outcome measures included the SF-36 Health Survey Questionnaire and additional generic and specific scales. During treatment, for all SF-36 summary and Hepatitis Quality of Life Questionnaire (HQLQ)-specific scales, the pegIFNα 2a group experienced less impairment than did the IFNα 2b/RBV patients. The between-treatment differences were significant for many of the scores particularly in the first 24 weeks of treatment. Across all measures of work functioning and productivity at each visit, patients randomized to pegIFNα 2a treatment showed less impairment relative to the group treated with IFNα 2b/RBV. Hence treatment with pegIFNα 2a relative to IFNα 2b/RBV minimizes the adverse impact of therapy on health-related QOL. Patients randomized to pegIFNα 2a had improved work productivity, less activity impairment, decreased need for prescription drugs to treat adverse effects, and better adherence to therapy.

KW - Hepatitis C infection

KW - Interferon alpha

KW - Quality of life

KW - Utilization of medical resources

UR - http://www.scopus.com/inward/record.url?scp=1642310280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642310280&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2893.2003.00482.x

DO - 10.1046/j.1365-2893.2003.00482.x

M3 - Article

VL - 11

SP - 157

EP - 165

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 2

ER -